Pharmacological management of atrial fibrillation: One, none, one hundred thousand

Sandro Gelsomino, Fabiana Lucà, Mark La Meir, Carmelo Massimiliano Rao, Orlando Parise, Ludovico Vasquez, Rocco Carella, Roberto Lorusso, Benedetto Daniela, Jos Maessen, Gian Franco Gensini

Research output: Contribution to journalArticle


Atrial fibrillation (AF) is associated with a significant burden of morbidity and increased risk of mortality. Antiarrhythmic drug therapy remains a cornerstone to restore and maintain sinus rhythm for patients with paroxysmal and persistent AF based on current guidelines. However, conventional drugs have limited efficacy, present problematic risks of proarrhythmia and cause significant noncardiac organ toxicity. Thus, inadequacies in current therapies for atrial fibrillation have made new drug development crucial. New antiarrhythmic drugs and new anticoagulant agents have changed the current management of AF. This paper summarizes the available evidence regarding the efficacy of medications used for acute management of AF, rhythm and ventricular rate control, and stroke prevention in patients with atrial fibrillation and focuses on the current pharmacological agents.

Original languageEnglish
Article number874802
JournalCardiology Research and Practice
Issue number1
Publication statusPublished - 2011

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Pharmacological management of atrial fibrillation: One, none, one hundred thousand'. Together they form a unique fingerprint.

  • Cite this

    Gelsomino, S., Lucà, F., La Meir, M., Rao, C. M., Parise, O., Vasquez, L., Carella, R., Lorusso, R., Daniela, B., Maessen, J., & Gensini, G. F. (2011). Pharmacological management of atrial fibrillation: One, none, one hundred thousand. Cardiology Research and Practice, 1(1), [874802].